DexCom, Inc. Stock News

DexCom, which has underperformed its medical equipment and S&P 500 peers in a big way in 2025, could be staring at better prospects next year. Stelo is facing vast and underpenetrated prediabetes and type-2 non-insulin markets, with potential international expansion likely in 2026. DXCM's solid FCF margins and cash reserves support a $750M buyback program, with 75% of authorization still availa...

NEW YORK , Dec. 15, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline. So what: If you purchased DexCom securities during the Class Period you may be entitled...

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).

NEW YORK , Dec. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

LOS ANGELES , Dec. 11, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  DexCom, Inc. ("DexCom " or "the Company") (NASDAQ: DXCM ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of DXCM during the class per...

The Touchstone Mid Cap Growth Fund outperformed its benchmark, the Russell Midcap® Growth Index, for the quarter ended September 30, 2025. From a factor perspective, the Fund's overweight exposure to size was a relative tailwind to performance, offsetting a headwind from being underweight volatility. Consumer Discretionary was the largest source of relative gains.

NEW YORK , Dec. 10, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline. So what: If you purchased DexCom securities during the Class Period you may be entitled...

NEW YORK , Dec. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.